Dublin, Dec. 19, 2016 -- Research and Markets has announced the addition of the "Pneumococcal Infections Drugs Price Analysis and Strategies - 2016" report to their offering.
Pneumococcal Infections Drugs Price Analysis and Strategies 2016, provides drug pricing data and benchmarks in the global Pneumococcal Infections market.
The research answers the following questions:
- What are the key drugs marketed for Pneumococcal Infections and their clinical attributes? How are they positioned in the Global Pneumococcal Infections market?
- What are the unit prices and annual treatment cost for Pneumococcal Infections therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
- What are the unmet needs in the global Pneumococcal Infections drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Pneumococcal Infections?
Research Scope:
- Treatment Options - Identify key drugs marketed and prescribed for Pneumococcal Infections including trade name, molecule name, and company
- Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Pneumococcal Infections
- Market Positioning - Identify how drugs are clinically and commercially positioned in the global Pneumococcal Infections market
- Pneumococcal Infections Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed
- Find out how the price advanced from 2012 and forecast to 2021
- Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape
- Pneumococcal Infections New Drug Pricing - Identify the effective pricing strategy for a new drug launch
Key Topics Covered:
1. Treatment Options
2. Drugs Clinical Attributes
3. Drugs Market Positioning
4. Drugs Price Analysis
5. Drugs Price Benchmarks
6. Drug Pricing & Reimbursement Landscape
7. Drugs Price Forecast
8. Market Unmet Needs
9. New Drug Pricing
For more information about this report visit http://www.researchandmarkets.com/research/jkm5z6/pneumococcal
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs


MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 



